Placing of new shares under general mandate
Filed with HKEX · Stock code 9926 · · 9 pages · English
Summary by 6ix AI
Akeso, Inc. has announced a placing of new shares under a general mandate, intending to issue a specific number of shares to professional and institutional investors. The company has conditionally agreed to place a significant number of shares at a determined price, which reflects a discount to recent trading prices. The proceeds from this placing are earmarked for research and development, commercialization of existing products, and general corporate purposes. Completion of the placing is subject to certain conditions, including approval from the Stock Exchange for the listing of the new shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Akeso
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- 2026 Interim report
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
- Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
- Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
Later from Akeso
- Completion of placing of new shares under general mandate
- Next Day Disclosure Return
- Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
- VOLUNTARY ANNOUNCEMENT - HARMONI-GI1 RESULTS PUBLISHED AT 2026 ESMO mOS 14.9m vs 12.1m, HR 0.75 (P=0.0031) FOR IVONESCIMAB PLUS CHEMO VS DURVALUMAB PLUS CHEMO IN 1L ADVANCED BTC
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2026
Follow Akeso into a list and get an email when it puts out news.
Follow Akeso